Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
8.5
来源：
Nature
关键字：
AI brain science
发布时间：
2025-10-08 19:33
摘要：
This systematic review and meta-analysis evaluates prognostic factors for oncologic outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA-targeted radioligand therapy (RLT). Key findings indicate that prior chemotherapy and the presence of visceral metastases, particularly liver metastases, are associated with poorer survival outcomes. Additionally, higher pretreatment SUVmean values correlate with improved overall survival, while significant PSA declines post-treatment are linked to better prognosis. These insights may guide clinical decision-making and patient selection for PSMA-RLT.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.0
关键证据
Prior chemotherapy use and location of metastases influence the prognosis of patients with mCRPC treated with PSMA-RLT.
Higher pretreatment SUVmean was associated with improved OS benefit.
PSA decline after treatment initiation, particularly ≥50%, was associated with improved PFS and OS.
真实性检查
否
AI评分总结
This systematic review and meta-analysis evaluates prognostic factors for oncologic outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA-targeted radioligand therapy (RLT). Key findings indicate that prior chemotherapy and the presence of visceral metastases, particularly liver metastases, are associated with poorer survival outcomes. Additionally, higher pretreatment SUVmean values correlate with improved overall survival, while significant PSA declines post-treatment are linked to better prognosis. These insights may guide clinical decision-making and patient selection for PSMA-RLT.